8. Lakins J, Bennett SA, Chen JH, Arnold JM, Morrissey C, et al. (1998) Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Biol Chem 273: 27887–95. 9. Miyake H, Nelson C, Rennie PS, Gleave ME (2000) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60: 170–6. 10. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, et al. (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50: 179–188. 11. Miyake H, Hara I, Fujisawa M, Gleave ME (2006) The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Exp Opin Invest Drugs 5: 507–17. 12. Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, et al. (2000) Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 60: 28–34. 13. Scaltriti M, Brausi M, Amorosi A, Caporali A, D’Arca D, et al. (2004) Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 108: 23–30. 14. Caporali A, Davalli P, Astancolle S, D’Arca D, Brausi M, et al. (2004) The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by Clusterin over-expression. Carcinogenesis 25: 2217–24. 15. Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, et al. (2004) Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis 7: 243–8. 16. Bettuzzi S (2003) The new anti-oncogene clusterin and the molecular profiling of prostate cancer progression and prognosis. Acta Biomedica Ateneo Parmense 74: 101–4. 17. Bettuzzi S, Rizzi F, Belloni L (2007) Clinical relevance of the inhibitory effect of Green Tea Catechins (GTCs) on prostate cancer progression in combination with molecular profiling of catechin-resistant tumors: an integrated view. Pol J Vet Sci 10: 57–60. 18. Rhodes D, Barrette T, Rubin M, Ghosh D, Chinnaiyan A (2002) Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427–33. 19. Scaltriti M, Belloni L, Caporali A, Davalli P, Remondini D, et al. (2006) Molecular classification of green tea catechin-sensitive and green tea catechin- resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis 27: 1047–53. 20. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, et al. (2002) Alpha-methylacyl- CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62: 2220–6. 21. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, et al. (2002) Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287: 1662–70. 22. Tinzl M, Marberger M, Horvath S, Chypre C (2004) DD3PCA3 RNA analysis in urine a new perspective for detecting prostate cancer. Eur Urol 46: 182–6. 23. Pegg AE, Williams-Ashman HG (1968) Biosynthesis of putrescine in the prostate gland of the rat. Biochem J 108: 533–9. 24. Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, et al. (2006) Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 14: 950–6. 25. Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, et al. (2006) Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 66: 1521–34. 26. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative Expression Software Tool (REST ) for group wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Research 30: e36. 27. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1463–7. 28. True L, Coleman I, Hawley S, Huang CY, Gifford D, et al. (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci 103: 10991–6. 29. Zhang XW, Yap YL, Wei D, Chen F, Danchin A (2005) Molecular diagnosis of human cancer type by gene expression profiles and independent component analysis. Eur J Hum Genet 13: 1303–11. 30. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, et al. (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8–15. 31. Rhodes JB, Williams-Ashman, HG (1964) Observations on polyamines in male accessory glands of reproduction. Int J Exp Med 10: 281–5. 32. Williams-Ashman HG, Pegg AE, Lockwood DH (1969) Mechanisms and regulation of polyamine and putrescine biosynthesis in male genital glands and other tissues of mammals. Adv Enzyme Regul 7: 291–323. 33. Sheth AR, Moodbidri SB (1977) Significance of polyamines in reproduction. Adv Sex Horm Res 3: 51–74. 34. Fair WR, Wehner N, Brorsson U (1975) Urinary polyamine levels in the diagnosis of carcinoma of the prostate. J Urol 114: 88–92. 35. Dudoit S, Fridlyand J, Speed T (2002) Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Ass 97: 77–87. Gene Signature 36. Li T, Zhang C, Ogihara M (2004) A comparative study of feature selection and multiclass classification methods for tissue classification based on gene expression. Bioinformatics 20: 2429–37. 37. Hastie T, Tibshirani R, Friedman J (2001) The Elements of Statistical Learning, Springer ed. 38. Schaefera KL, Eisenacherb M, Brauna Y, Brachwitza K, Waic DH, et al. (2008) Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 44: 699–709. 39. Barrier A, Lemoine A, Boelle PY, Tse C, Brault D, et al. (2005) Colon cancer prognosis prediction by gene expression profiling. Oncogene 24: 6155–64. 40. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790–9. 41. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, et al. (2008) Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 68: 152–60. 42. Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, et al. (2005) Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 174: 514–8. 43. Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, Terry TR, et al. (1999) Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res 5: 569–76. 44. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, et al. (2005) Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5: 45. 45. Scattoni V (2006) Systematic prostate biopsies are more and more often becoming saturation biopsies. Eur Urol 50: 202–4. 46. Chrouser KL, Lieber MM (2004) Extended and saturation needle biopsy for the diagnosis of prostate cancer. Curr Urol Rep 5: 226–30. 47. Cheng L, Paterson RF, Beck SD, Parks J (2004) Prostatic intraepithelial neoplasia: an update. Clin Prostate Cancer 3: 26–30. 48. Sakr W, Partin AW (2001) Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology 57: 115–20. 49. Crissman JD, Sakr WA, Hussein ME, Pontes JE (1993) DNA quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate. Prostate 22: 155–62. 50. Astancolle S, Guidetti G, Pinna C, Corti A, Bettuzzi S (2000) Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment. J Endocrinology 167: 197–204. 51. Crescioli C, Ferruzzi P, Caporali A, Mancina R, Comerci A, et al. (2003) Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 144: 3046–57. 52. Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, et al. (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 150: 591–603. 53. Rosenberg ME, Silkensen J (1995) Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 27: 633–45. 54. Koch-Brandt C, Morgans C (1996) Clusterin: a role in cell survival in the face of apoptosis? Prog Mol Sub Biol 16: 130–149. 55. Reddy KB, Jin G, Karode MC, Harmony JAK, Howe PH (1996) Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/ CLU in epithelial cells. Biochemistry 35: 6157–63. 56. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, et al. (2000) Nuclear CLU/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci 97: 5907–12. 57. Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, et al. (2004) Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. BJU Int 91: 1842–50. 58. Caccamo AE, Scaltriti M, Caporali A, D’Arca D, Corti A, et al. (2005) Ca2+ depletion caused nuclear translocation of a 45 kDa death-isoform of clusterin and anoikis induction in prostate cells. Cell Death Diff 12: 101–4. 59. Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, et al. (2005) Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep 14: 1371–5. 60. Gleave M, Miyake H (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urology 23: 38–46. 61. Lapointe J, Li C, Higgins J, van de Rijn M, Bair E, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811–6. 62. Bettuzzi S, Scorcioni F, Astancolle A, Davalli P, Scaltriti M, et al. (2002) Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40- immortalised human prostate epithelial cells by slowing down cell cycle progression. Oncogene 21: 4328–34. 63. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S (2004) Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res 64: 6174–82. PLoS ONE | www.plosone.org 8 October 2008 | Volume 3 | Issue 10 | e3617